Imperial College London
Alternate

Professor Peter GJ Burney MA MD FRCP FFPHM FMedSci

Faculty of Medicine, National Heart & Lung Institute

Emeritus Professor of Respiratory Epidemiology
 
 
 
//

Contact

 

+44 (0)20 7594 7941p.burney

 
 
//

Location

 

07Emmanuel Kaye BuildingRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Janson:2019:10.1183/13993003.00561-2019,
author = {Janson, C and Malinovschi, A and Amaral, A and Accordini, S and Bousquet, J and Buist, S and Canonica, G and Dahlen, B and Garcia, Aymerich J and Gnatiuc, L and Kowalski, M and Patel, J and Tan, W and Toren, K and Zuberbier, T and Burney, P and Jarvis, D},
doi = {10.1183/13993003.00561-2019},
journal = {European Respiratory Journal},
title = {Bronchodilator reversibility in asthma and COPD: Findings from three large population studies},
url = {http://dx.doi.org/10.1183/13993003.00561-2019},
volume = {54},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Bronchodilator response (BDR) testing is used as a diagnostic method in obstructive airway diseases. The aim of this investigation was to compare different methods for measuring BDR in participants with asthma and COPD and to study to the extent to which BDR was related to symptom burden and phenotypic characteristics.Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) was measured before and 15min after 200μg of salbutamol in 35628 subjects aged 16years and older from three large international population studies. The subjects were categorised in three groups: current asthma (n=2833), COPD (n=1146), and no airway disease (n=31649). Three definitions for flow related (increase in FEV1) and three for volume related (increase in FVC) were used.The prevalence of bronchodilator reversibility expressed as increase FEV1≥12% and 200mL was 17.3% and 18.4% in participants with asthma and COPD, respectively, while the corresponding prevalence was 5.1% in those with no airway disease. In asthma, bronchodilator reversibility was associated with wheeze (OR (95% CI): 1.36 (1.04–1.79)), atopy (OR 1.36 (1.04–1.79)) and higher FeNO while in COPD neither flow nor volume related bronchodilator reversibility was associated with symptom burden, exacerbations or health status after adjusting for prebronchodilator FEV1.Bronchodilator reversibility was at least as common in participants with COPD as those with asthma. This indicates that measures of reversibility are of limited value for distinguishing asthma from COPD in population studies. In asthma, however, bronchodilator reversibility may be a phenotypic marker.
AU  - Janson,C
AU  - Malinovschi,A
AU  - Amaral,A
AU  - Accordini,S
AU  - Bousquet,J
AU  - Buist,S
AU  - Canonica,G
AU  - Dahlen,B
AU  - Garcia,Aymerich J
AU  - Gnatiuc,L
AU  - Kowalski,M
AU  - Patel,J
AU  - Tan,W
AU  - Toren,K
AU  - Zuberbier,T
AU  - Burney,P
AU  - Jarvis,D
DO  - 10.1183/13993003.00561-2019
PY  - 2019///
SN  - 0903-1936
TI  - Bronchodilator reversibility in asthma and COPD: Findings from three large population studies
T2  - European Respiratory Journal
UR  - http://dx.doi.org/10.1183/13993003.00561-2019
UR  - http://hdl.handle.net/10044/1/70941
VL  - 54
ER  -
Download